Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer (beta)

Based on guidelines from the American Society of Clinical Oncology.

Strength

Strong recommendation

Moderate recommendation

Weak recommendation

Evidence

High quality evidence

Intermediate quality evidence

Low quality evidence

Insufficient evidence

N/A

Optimal Duration

High Risk of Recurrence (T4 and/or N2)

For patients with high-risk (T4 and/or N2) stage III resected colon cancer, adjuvant oxaliplatin-containing chemotherapy should be offered for a duration of 6 months.
Moderate recommendation
Intermediate quality evidence

Low Risk of Recurrence (T1, T2, or T3 and N1)

For patients with low-risk (T1, T2, or T3 and N1) stage III resected colon cancer, adjuvant oxaliplatin-containing chemotherapy may be offered for a duration of 3 months or 6 months after a discussion with the patient of the potential benefits and risks of harm associated with the options for treatment duration.
Moderate recommendation
Intermediate quality evidence

Approach

A shared decision-making approach should be used for duration of oxaliplatin-containing chemotherapy for patients with stage III resected colon cancer, taking into account a patient’s tumor characteristics, completeness of surgical resection, number of lymph nodes examined, comorbidities, functional status, performance status, values and preferences, age at diagnosis, life expectancy, potential years at risk for long-term sequalae of treatment, and including a discussion of the potential for benefit and risks of harm associated with treatment duration.
Strong recommendation
N/A